ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Apnimed raises funding to advance sleep apnea therapeutic
March 29, 2021Apnimed has raised $25m in a Series B financing round to advance its oral disease-modifying therapeutic AD109 for obstructive sleep apnea (OSA) and support its ongoing development and commercialisation plans. -
Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea
November 27, 2020Apnimed announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.
Pharma Sources Insight January 2025
